L-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND

David A. Davis, PhD, Paul Alan Cox, PhD, Sandra Anne Banack, PhD, Patricia D. Lecusay, HT(ASCP), Susanna P. Garamszegi, BSc, Matthew J. Hagan, BSc, James T. Powell, MSc, James S. Metcalf, PhD, Roberta M. Palmour, PhD, Amy Beierschmitt, DVM, Walter G. Bradley, DM, and Deborah C. Mash, PhD

Abstract

The early neuropathological features of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) are protein aggregates in motor neurons and microglial activation. Similar pathology characterizes Guamanian ALS/Parkinsonism dementia complex, which may be triggered by the cyanotoxin β-N-methylamino-L-alanine (BMAA). We report here the occurrence of ALS/MND-type pathological changes in vervets (Chlorocebus sabaeus; n = 8) fed oral doses of a dry powder of BMAA HCl salt (210 mg/kg/day) for 140 days. Spinal cords and brains from toxin-exposed vervets were compared to controls fed rice flour (210 mg/kg/day) and to vervets coadministered equal amounts of BMAA and L-serine (210 mg/kg/day). Immunohistochemistry and quantitative image analysis were used to examine markers of ALS/MND and glial activation. UHPLC-MS/MS was used to confirm BMAA exposures in dosed vervets. Motor neuron degeneration was demonstrated in BMAA-dosed vervets by TDP-43+ proteinopathy in anterior horn cells, by reactive astroglisis, by activated microglia, and by damage to myelinated axons in the lateral corticospinal tracts. Vervets dosed with BMAA + L-serine displayed reduced neuropathological changes. This study demonstrates that chronic dietary exposure to BMAA causes ALS/MND-type pathological changes in the vervet and coadministration of L-serine reduces the amount of reactive gliosis and the number of protein inclusions in motor neurons.

Key Words: ALS/MND, BMAA, Cyanobacteria, Guam ALS/PDC, Motor neurons, Neurofibrillary tangles, TDP-43.

INTRODUCTION

Amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) is a progressive MND characterized by rapidly progressing upper and lower motor neuron degeneration, profound muscle atrophy and paralysis, and a mean survival of 2–5 years of life after diagnosis (1). Despite significant progress in understanding the genetic basis of familial cases, 90% of these cases are sporadic in nature and poorly understood (2). While ALS/MND may be a syndrome rather than a single disease, the early neuropathological changes (3) are similar with activation of microglia, the resident macrophage population in the CNS, often presaging the eventual damage and loss of motor neurons in the spinal cord (4). Protein inclusions, particularly in anterior horn motor neurons, astrogliosis, and the loss of myelinated axons in the lateral corticospinal tracts are features of degeneration of upper and lower motor neurons (5).

The majority of the ALS/MND experimental models developed to date are based on known gene mutations (e.g. C9orf72, FUS, SOD1, and TARDBP). These animal models demonstrate neuropathological changes in motor neurons but rarely include the progressive neurodegenerative process as a whole consistent with the earliest stages of the clinical disease (5–7) or gene-environment-time interactions (8). Furthermore, these genetic mutations only represent 10% of all ALS/MND patients (9). Thus, an in vivo model, which includes the neuropathological changes that occur in presymptomatic individuals, would be useful for testing novel therapeutic strategies to prevent disease progression (10) and death of motor neurons.

The neuropathology of ALS/MND is similar to the paralytic disease suffered by the indigenous Chamorro people of Guam. Guam ALS/Parkinsonism dementia complex (PDC) includes symptoms of upper and lower motor neuron degeneration and resultant muscle atrophy, as well as protein inclusions in the spinal cord anterior horn (11). Early work

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
suggesting that the Chamorro traditional diet was implicated in Guam ALS/PDC etiology, particularly flour made from the seeds of Cycas microsperma Hill (Cycadaceae) (12–14) led to the identification of the neurotoxic nonprotein amino acid β-N-methylamino-l-alanine (BMAA), produced by cyanobacteria in specialized roots of the cycad trees (15). BMAA was shown to accumulate in tissues of volant mammals consumed by the Chamorros (16), and to be present in tortillas and dumpings made from cycad seed flour, and thus to bioaccumulate in the brains of the Chamorros suffering from ALS/PDC (15, 16). By chronically feeding BMAA to vervets for 140 days, we demonstrated for the first time a similar neuropathology in the brain to that seen in humans with Guamanian ALS/PDC (17, 18).

BMAA is produced by all free-living cyanobacteria indicating that exposure can occur outside the Guam ecosystem (19, 20). Consumption of contaminated seafood (21–23) and living near water bodies with frequent algal blooms (24) have both been proposed as risk factors for BMAA exposure. BMAA rapidly crosses the blood-brain barrier to accumulate in the CNS and localize to neurons (25, 26). Brain uptake leads to neurotoxic injury through a variety of mechanisms, including damage to Nicotinamide adenine dinucleotide phosphate diaphorase-positive motor neurons, overstimulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors, abnormal hyperphosphorylation, mitochondrial damage, gliotoxicity, and protein misfolding (27–32). Protein misincorporation of BMAA for l-serine in SOD1 (33), albeit a relatively rare event, may lead to dissociation of the SOD1 dimer, subsequent protein misfolding, and nucleation of protein aggregates in neurons and glia (31). Thus, BMAA exposures to the brain can affect select subpopulations of motor neurons, astroglia, and microglia.

Our laboratory has previously demonstrated that chronic dietary exposure to BMAA triggers β-amyloid deposits, neurofibrillary tangles (NFTs), and glial inclusions in the cerebral cortex, including the primary motor cortex of vervets (18). In this study, we have extended our original experimental findings to examine if the same chronic BMAA exposures in the diet cause degeneration in the upper motor neuron tracts and lower motor neurons in the spinal cord. We conducted this investigation in vervets in parallel with autopsied brain and spinal cord tissues from a patient diagnosed with sporadic ALS/MND (sALS) for diagnostic neuropathology marker comparisons. We report here that chronic dietary exposure to BMAA in vervets leads to anterior horn neuron injury, TDP-43 proteinopathy, glial activation, and loss of myelinated axons in the lateral corticospinal tracts. Coadministration of l-serine reduced these neuro-pathological changes, protecting motor neuron injury from chronic exposure to BMAA.

**MATERIALS AND METHODS**

**Toxin Dosing**

Young adult male vervets (*Chlorocebus sabaeus*; age 7 years; 3.1 kg) were housed in groups inside large outdoor enclosures at the Behavioural Science Foundation (BSF) (St. Kitts, West Indies). The BSF is a fully accredited biomedical research facility with approvals from the Canadian Council on Animal Care. The BSF Institutional Animal Care and Use Committee approved the use of our experimental protocol for this study. During the dosing experiment, vervets ate a low-protein diet comprising predominantly local fruits and vegetables. For dietary exposure, l-BMAA HCl, l-BMAA HCl plus l-serine, or rice flour was placed inside a cavity of a banana and presented to vervets prior to their daily allotment of food. l-BMAA HCl salt was synthesized by Irvine Chemistry Lab (Anaheim, CA), with purity confirmed by 1H NMR and 13C NMR. Optical rotation was c = 1.15 mg/mL in 5N HCl, +27.7°C, with a melting point of 186–190°C (Cox et al 2016 Supplementary Material). In tandem LC/MS/MS, the synthesized BMAA was consistent in mass, product ions, and product ion ratios with an authenticated standard (B-107, Sigma-Aldrich, St. Louis, MO). Vervets were randomly assigned to one of three 8-member cohorts for 140 days of dosing with l-BMAA HCl at 210 mg/kg/day, l-BMAA HCl plus l-serine both at 210 mg/kg/day, and a control cohort dosed with 210 mg/kg/day of rice flour. The 140-day BMAA dosing regimen of the adult vervet was calculated to be equivalent to the 20-year lifetime exposure of an adult Chamorro male consuming a 30-g serving of cycad powder per day in tortillas and 8 flying foxes (*Pteropus mariannus*) per month (17). Group enclosures for each vervet cohort were spaced appropriately apart to reduce the chance for sharing bananas to cause cross contamination. The 210 mg/kg of powdered l-BMAA HCl delivered an effective daily dose of 161 mg/kg l-BMAA HCl (17, 18). The doses were prepared at Brain Chemistry Labs (Jackson, Wyoming) using a Mettler Toledo balance with a Quantos automated powder-dispensing module at a tolerance of ±0.1% of target dose. To ensure oral delivery of test substances, veterinarian, BSF and Brain Chemistry Labs staff monitored daily dosing. Cerebral spinal fluid, hair, and plasma were sampled every 4 weeks from each vervet under ketamine anesthesia, and body weight was recorded. All vervets were observed daily for mortality, morbidity, and clinical signs of adverse health effects and qualitative food consumption.

**Necropsy and Histopathology**

After the 140-day, chronic dosing regimens, vervets were euthanized under ketamine anesthesia followed by complete dissection of brain and spinal cord tissues. All the external surfaces of specimens were examined, photographed, and fixed in 10% neutral buffered formalin for histopathological studies. Brain tissues were placed into phosphate buffered saline (PBS), pH 7.4, and shipped to NeuroScience Associates (Knoxville, TN) for processing, embedding, and sectioning into 40 μm sections on 76 × 51 mm glass slides using the Multibrain Service. Spinal cord tissues were processed using xylenes and alcohols and transverse segments were embedded in paraffin wax in preparation for Leica microtome sectioning into 7-μm sections on 75 × 25 mm glass slides. Slide mounts of 3 cervical and 3 lumbar spinal cord segments were paraffinized in 3 changes of xylene for 10 minutes each, followed by 2 changes of absolute ethanol for 5 minutes each, then 95% ethanol for 5 minutes. Routine histological stains included he-
matoxylin and eosin (H&E), periodic acid-Schiff, luxol fast blue, thionine-Nissl, and thioflavin-S. To probe for specific protein antigens after hydration, slide tissue mounts were incubated in 3% H₂O₂ in methanol for 10 minutes followed by rinsing in distilled water for 3 changes of 5 minutes. Slides were then incubated in antigen retrieval buffer (98% formic acid for 45 seconds or citrate buffer for 30 minutes, where applicable), followed by a wash in 3 changes of distilled H₂O on a Thermolyne Roto Mix shaker and incubation in PBS for 5 minutes. To block nonspecific antibody binding, 10% normal donkey serum (NDS) in PBS was applied to slides in a humidty chamber and incubated at room temperature for 30 minutes. Brain and spinal cord slide mounts were probed with antibodies against β-amyloid (Aβ; 1:800, Covance, Princeton, NJ), cluster of differentiation 68 (CD68; 1:500, DAKO/Agilent, CA), fused in sarcoma (FUS; 1:2000, Novus Biological, Centennial, CO), ionized calcium binding adaptor molecule 1 (Iba1; 1:300, FUJIFILM Wako Chemicals, Richmond, VA), glial fibrillary acidic protein (GFAP; 1:1000, Sigma-Aldrich), phospho-tau (Ser202, Thr205) monoclonal antibody (AT8; 1:3000, Thermo Fischer Scientific, Waltham, MA), phosphorylated TAR DNA-binding protein 43 (TDP-43; 1:1000, Cosmo-Bio, Carlsbad, CA), and ubiquitin (Ubiq; 1:300, Millipore, Waltham, MA). Slides were incubated with antibodies at 4°C overnight. Slides were rinsed with PBS for 3 changes of 10 minutes, followed by additional application of 2% NDS for 10 minutes prior to incubation with secondary antibodies. A donkey anti-mouse biotin (1:200; Jackson Immunoresearch, West Grove, PA) conjugated secondary antibody goat anti-mouse/or anti-rabbit was incubated on tissue sections for 2 hours at room temperature, rinsed with a PBS wash for 10 minutes, and followed by application of ExtrAvidin peroxidase (1:5000, Sigma-Aldrich) in PBS for 1 hour. ExtrAvidin peroxidase was detected using diaminobenzidine (DAB) solution (100 mL DAB = 98 mL PBS + 2 mL 25 mg/mL DAB + 16.6 mL 3% H₂O₂) for 10 minutes. Slides were washed in 2 changes of PBS, rinsed with distilled water, and counterstained with Gill No. 1 hematoxylin for 20 seconds and rinsed under running tap water for 5 minutes. Phospho-Tau AT8 immunohistochemistry was performed on cortical brain sections by Neuroscience Associates. Sevier Münger silver staining was performed at AML Laboratories (Jacksonville, Florida) and counterstained with Gill No. 1 hematoxylin. Post-mortem spinal cord and brain tissues from a 58-year-old Caucasian male with a neuropathologically confirmed diagnosis of sALS were used as positive controls with each immunostaining protocol.

**Digital Pathology and Microscopy**

Histology slides were scanned at 40× resolution using a TissueScope LE (Huron Digital Pathology, Waterloo, Ontario, Canada). Digital scanning allowed for complete mapping of entire spinal cord sections and clear visualization of margins and anatomical landmarks at an optimal resolution of (0.2 μm/pixel [Px]) at 40× for image analysis. High quality tiff image file (1721 × 985 Px or 3259 × 1174 Px) fields were exported from TissueScope LE and imported in NIH ImageJ 64 VER1.44o (NIH, Bethesda, MD) for analysis. To determine

**Detection and Quantification of BMAA Toxin**

Spinal cord tissues were analyzed to measure the concentration of BMAA using triple quadrupole tandem mass spectrometry (UHPLC-MS/MS) with a precolumn 6-aminoquinolinyl-N-hydroxysuccinimidy carbamate (AQC) derivatization employing a method validated according to peer AOAC International guidelines and previously reported (17, 34) (Supplementary Fig. S2). Spinal cord samples (50 mg) were extracted with Trichloroacetic Acid (TCA) (20% w/v) for free BMAA followed by HCl (6.0 M) hydrolysis of the pellet at 110°C for 16–18 hours to release protein-bound BMAA. The presence of BMAA in the supernatant after TCA extraction was checked by further HCl hydrolyzation of the supernatant. Extracted samples were filtered using a centrifuge filter (0.2 μm, Millipore UltrafreeMC) at 14 000 g for 5 minutes and analyzed on a Thermo Scientific TSQ Quantiva triple quadrupole mass spectrometer attached to a Thermo Vanquish Ultra-High Pressure Liquid Chromatography Autosampler equipped with a Vanquish pump and column compartment. Separation of 4 BMAA structural isomers (N-[2-aminoethyl] glycine, 2,3-diaminobutanoic acid, 2,4-diaminobutyric acid, and β-amino-N-methyl-alanine) was achieved with gradient elution using 20 mM ammonium acetate, pH 5.0 (A) and 100% methanol (B) as follows: 0.5 mL/minutes, 0 minutes 10% B, 1.0 minutes 10% B, 4.8 minutes 40% B (curve 5), 5.0 minutes 90% B (curve 5), 6.8 minutes 90% B, 6.81 minutes 10% B (curve 5), and 8 minutes 10% B. Separation was performed using a Thermo Hypersil Gold C-18 column (PN 25002-102130) 100 × 2.1 mm, particle size 1.9 μm heated to 65°C. Samples were analyzed in positive ion, single reaction monitoring mode using heated electrospRAY ionization using previously published ion transitions (18). Mass spectrometer ion source properties were as follows: 3500 V-positive ion, 45 Arb Sheath gas, 10 Arb Aux gas, Sweep gas 0.1 Arb, vaporizer temperature 400°C, and ion transfer tube temperature 350°C. Validation curves and parameters were performed as in Glover et al (34) passing all criteria exceeding minimum requirements for a single-laboratory validation. Limit of Detection (0.009 ng/mL) and Lower Limit of Quantification (0.037 ng/mL) were calculated according to U.S. Food and Drug Administration recommended regulatory guidelines (35). All samples were run and normalized with an internal BMAA standard (β-N-methyl-d₃-α-methyl-α-alanine,¹⁵N₂) at a concentration of 1.5 ng/mL. System blanks (AQC derivatized blanks, internal standards, and deionized water) were injected between sample injections.
TABLE 1. Detection of Free and Protein-Bound BMAA in Vervet Spinal Cord

| Exposure Cohort | Free (μg/g) | Hydrolyzed Protein Pellet (μg/g) | Hydrolyzed Supernatant (μg/g) |
|-----------------|------------|---------------------------------|-------------------------------|
| Rice flour      | ND         | ND                              | ND                            |
| BMAA            | 8.9 ± 3.9NS | 0.5 ± 0.3NS                      | 34.0 ± 20.5 NS                |
| BMAA + L-serine | 9.4 ± 2.2  | 0.6 ± 0.1                        | 56.2 ± 13.6                   |

Median ± SEM of BMAA per gram of spinal cord tissues; ND, not detected; NS, no statistically significant differences were found between groups using a nonparametric Mann-Whitney U test.

Statistical Analyses

Prism Version 7 software (Graph Pad, La Jolla, CA) was used to perform statistical analyses. Single comparisons tests were analyzed using Student t test and Mann-Whitney U test. Multiple comparisons were analyzed using one-way analysis of variance (ANOVA) with Newman-Keuls Multiple Comparison test, the Friedman with Dunn’s multiple comparison tests, or the Wilcoxon match pairs sign test. For correlation analyses, Pearson’s correlation coefficient and Spearman correlation tests were used to determine significance. D’Agostino and Pearson test was used to determine normality of each data set. All data were expressed as the median ± standard error; significance level of α = 0.05. Due to the limited size of our sample cohort, Cohen’s f was used to determine effect size. A table of descriptive statistics for each statistical comparison can be found in the Supplementary Table S1.

RESULTS

Toxin Accumulation

Spinal cord tissues collected at necropsy from BMAA and BMAA + L-serine cohorts were both positive for the cyanobacterial toxin (Table 1 and Supplementary Fig. S2). As expected, the rice flour control group had no detectable levels of BMAA (Table 1). The median total BMAA concentration in spinal cord tissues was 61.4 μg/g ± 13.7 SE and ranged from 15.8 to 199.9 μg/g in the BMAA and BMAA + L-serine dosing cohorts. The median and range of concentration of detectable BMAA in vervets were similar to those measured in cortical brain tissues from individuals with Guam ALS/PDC (36) and spinal cords from North Americans with ALS/MND (37). The concentrations of free and protein-bound BMAA were positively correlated (r = 0.919, p < 0.0001). In addition to these two protein fractions, considerable BMAA was found in the hydrolyzed supernatant indicating small soluble peptides present in spinal cord tissues (Table 1). Coadministration of L-serine did not significantly reduce the median concentration of BMAA, in any fraction of the vervet spinal cord (Table 1 and Supplementary Table S1).

Anterior Horn

Microscopic examination of lower motor neurons of the cervical spinal cord anterior horns of BMAA-dosed vervets showed 4.3-fold greater frequency of eosinophilic neurons (p = 0.024) that were reduced 40% in size (p ≤ 0.0001) and contained abundant skeinlike cytoplasmic vacuoles (p = 0.0002) that were absent in controls dosed with rice flour (Fig. 1A–H and Supplementary Fig. S3). Anterior horn neuronal numbers were decreased by 23% (p = 0.0016) and a portion was observed to have thinning of Nissl substances and chromatolysis (Fig. 1I–L, N and Supplementary Fig. S3). Bunina bodies, a pathological hallmark of ALS/MND (38) and Guam ALS/PDC (11), were also observed in spinal cord motor neurons of vervets dosed with BMAA (Fig. 1M). The accumulation of glycogen (Fig. 1K, O), a sign of metabolic dysfunction (39), along with cell death and neuronophagia was also present in anterior horn neurons (Fig. 1P). Other qualitative markers of ALS/MND-type cellular injury included the intracellular accumulation of thioflavin-S + plaques (40) and dystrophic argyrophilic neurons similar to NFTs (41) were abundant in the BMAA-dosed cohort, but not observed in rice flour-fed primates (Fig. 2). Extracellular amyloid beta plaques were not observed in the spinal cords of any cohort.

Protein inclusions in anterior horn cells typically associated with the diagnosis of ALS/MND were also found in the BMAA-dosed vervet cohorts. Neurons from 12 of 16 (75%) of vervets fed BMAA were positive for TDP-43 dense, granular, and round cytoplasmic inclusion bodies (Fig. 3A–D and Table 2) (42). The mean density and distribution of TDP-43 + inclusions in toxin-dosed vervets were 5-fold greater (p = 0.024) than those observed in controls, which is similar to that observed in Guam ALS/PDC (43) (Table 2). Rare cytoplasmic mislocalization of FUS + protein, a marker used in postmortem diagnosis of TDP-43-negative ALS/MND patients (44), was observed in 2 of the 16 (12.5%) of BMAA-dosed vervets (Fig. 3E–H). Anterior horn neurons and glia also displayed UBQ + cytoplasmic inclusions and neurites (Fig. 3I–L). The presence of both TDP-43 + and UBQ + protein inclusions along with Bunina bodies in anterior horn neurons suggests that chronic BMAA dosing causes motor neuron injury in vervets characteristic of ALS/MND and Guam ALS/PDC (45).

Astrogliosis are nonneuronal cells that support neuronal plasticity, modulate synaptic transmission and have been previously shown to be susceptible to BMAA toxicity (25, 46, 47). In our study, vervets receiving fruit supplemented with rice flour displayed only astrogliosis with normal cellular architecture that were distributed adjacent to healthy motor neurons in the spinal cord (Fig. 4A–C). Chronic dietary dosing with BMAA increased the density of GFAP + activated astroglia 1.4-fold (p = 0.008) in the vicinity of atrophic and vacuolated motor neurons in the anterior horns of the lumbar spinal cord (Fig. 4D–F, K). GFAP + astroglia in BMAA-dosed vervets displayed morphological changes similar to those found in a sALS patient (Fig. 4G–I). Reactive astrogliosis was also ob-
served in the primary motor cortex and midbrain with decreasing density progressing down the neuroaxis of toxin-dosed vervets (Supplementary Fig. S4A–D). Coadministration of L-serine reduced the total number \( p = 0.008 \) and total area \( p = 0.007 \) of GFAP\(^+\) astroglia in the anterior horn of the lumbar spinal cord by 21% and 20%, respectively (Fig. 4K, L).

**Lateral Corticospinal Tract**

Microglia are resident macrophage/immunocells of the central nervous system that play an important role in synaptic regulation and modulation of neuron networks, as well as inflammation and scavenging. Microglial activation is one of the earliest pathological changes in ALS/MND (48). Chronic dietary dosing with BMAA increased the density 1.7-fold \( p = 0.048 \) and total area 1.6-fold \( p = 0.011 \) of IbA1\(^+\) microglia in the cervical spinal cord of vervets compared to controls fed rice flour (Figs. 5A–F and 6A–F). BMAA effects on IbA1\(^+\) microglia in the spinal cord were region-specific and targeted predominantly to descending motor pathways. Ascending white matter tracts such as the dorsal column, the spinothalamus, and the anterolateral system were unaffected (Figs. 5D and 6B, C and Supplementary Fig. S1). IbA1\(^+\) microglia were observed forming large nodule-type lesions (49) and phagocytes in the lateral corticospinal tracts of BMAA-dosed vervets, but not in rice flour controls (Figs. 5A–
The density and the total area covered by Iba1+ microglia were 1.5-fold (p = 0.0039) greater in the cervical compared to the lumbar segments of the spinal cord from BMAA-dosed vervets (Table 3). Iba1+ microglia nodules were also observed in the pyramids of the medulla, the cerebral peduncles, and cortical areas of BMAA-dosed vervets (Supplementary Fig. S4E–H).

CD68, a marker of proinflammatory microglial activation, was bilaterally expressed in the lateral corticospinal tracts in both cervical and lumbar segments of the spinal cord of BMAA-dosed vervets (Fig. 5G–I). CD68+ microglial density and distribution observed in BMAA-dosed vervets were similar to those seen in a representative autopsy specimen from an individual with neuropathologically confirmed sALS (Fig. 5J–L). CD68+ nodules had increased number and size (p/C20 0.0001) compared to those of control vervets (Figs. 5G–I and 6G). In addition to proinflammatory microglial activation, we observed pallor of myelin staining in the pyramidal tracts suggesting mild loss of myelinated axon fibers in the lateral corticospinal tracts in 7 of 16 (44%) of vervets fed BMAA (p = 0.0956) (Fig. 7 and Supplementary Table S1). The mean Iba1+ microglia distribution and CD68+ microglial expression in the lateral corticospinal tract stimulated by BMAA dosing was attenuated 32% and 24%, respectively by coadministration of l-serine (Fig. 6 and Table 3).

Corticospinal Pathology

Guam ALS/PDC is characterized by the presence of dense and widely distributed cortical NFTs affecting motor, sensory, and association areas of the cerebral cortex (11). Chronic dietary exposure to BMAA triggered cortical NFTs in the vervet with a density and distribution similar to Guam ALS/PDC (17, 18, 50). To investigate the relationship between BMAA-induced cortical and spinal cord pathologies, the median tau AT8+ NFT density in the same vervets was calculated across seven cortical brain regions. Chronic BMAA exposure increased the median tau AT8+ NFT density by 3.1-fold (p ≤ 0.0001) and was attenuated 40% by coadministration of l-serine (Fig. 8A, B). Cortical AT8+ NFT density deposition observed in BMAA-dosed vervets was also positively correlated with the concentration of BMAA detected in the spinal cord as a marker of exposures (r = 0.6804, p = 0.0004) (Fig. 8C) and the ALS/MND-type pathology observed in descending white matter tracts and the anterior horns. Cortical AT8+ NFT density was positively correlated with the total area of Iba1+ microglia in the lateral corticospinal tract (r = 0.6399, p = 0.0004) (Fig. 8D), the density and distribution of TDP-43+ cytoplasmic inclusion in motor neurons (r = 0.4905, p = 0.01) (Fig. 8E), and the number of reactive GFAP+ astroglia adjacent to those motor neurons (r = 0.6488, p = 0.0003) (Fig. 8F). In all these correlation analyses, coadministration of l-serine decreased the degree of the ALS/MND-type pathological changes observed in the cerebral cortex, anterior horn, and lateral corticospinal spinal tracts (Fig. 8C–F). These observations suggest that chronic dietary exposure to BMAA induces degeneration of upper and lower motor neurons in vervets and coadministration of l-serine reduces these pathological changes.

DISCUSSION

We report here that chronic dietary exposure to the cyanotoxin BMAA induces ALS/MND-type degeneration of the upper and lower motor neurons in a vervet model. This includes protein inclusions in anterior horn motor neurons, lower motor neuron degeneration, reactive astrogliosis, and microglial activation characteristic of axonal damage and loss of myelinated...
fibers in the primary descending motor pathways of the vervet spinal cord. The vervet BMAA toxin exposure model recapitulates the features of Guam ALS/PDC and ALS/MND neuropathology including degeneration of both upper and lower motor neurons and TDP-43+ neuronal inclusions (43, 51). It is noteworthy to mention that the vervet carries the APOE4 genotype (52), which may explain the prevalence of cortical AT8+ NFTs, in keeping with the cortical dementia associated with Guam ALS/PDC (11, 53). These data suggest that BMAA-exposed vervets may serve as a useful experimental model for testing novel therapeutics for the treatment of ALS/MND.

In the vervet, L-serine attenuates the occurrence of NFTs in upper motor neurons of the primary motor cortex (18). In the spinal cord, we observed rare NFTs in BMAA-fed vervets,
consistent with what has been observed in Guamanian ALS/PDC patients (53). In addition, we found evidence of other neuronal protein inclusions characteristic of ALS/MND, including TDP-43\(^+\), FUS\(^+\), UBIQ\(^+\), and Bunina bodies. L-Serine coadministration with BMAA reduced the number of anterior horn neuron protein inclusions, microglial activation, and reactive astrogliosis. Moreover, L-serine protected against the overall development of cortical NFTs and reduced pathology leading to axonal damage in the lateral corticospinal tracts in the vervet BMAA model.

In vitro, L-serine inhibits misincorporation of BMAA into proteins (54) and modulates the endoplasmic reticulum unfolded protein response (55). In our vervet study, coadministration of L-serine did not reduce the amount of free BMAA nor did it decrease the detection of BMAA measured in the protein fraction. This observation suggests that alternative mechanisms of neuroprotection, unrelated to protein misfolding or dysfunction may explain the results observed in vervets. Other possible mechanisms for L-serine neuroprotection include proliferation of oligodendrocytes stimulating myelin repair (56) or restoring serine homeostasis through racemase conversion of L- to D-serine (57). L-Serine uptake by astroglia may lead to a compensatory increase in D-serine following dietary BMAA exposures. D-Serine is a glutamate antagonist at AMPA/kainate receptors, which could offset the excitotoxic effects of BMAA binding to NMDA receptors on motor neurons (27, 58, 59).

L-Serine has been suggested to have therapeutic benefit for alleviating symptoms associated with some neurological diseases (56, 57, 60–63). Currently, a phase IIa trial in ALS/PDC patients (53) has been initiated. In the vervet model, L-serine coadministration with BMAA also reduced the number of anterior horn neuron protein inclusions, microglial activation, and reactive astrogliosis. Furthermore, L-serine protected against the overall development of cortical NFTs, decreased pathology leading to axonal damage in the lateral corticospinal tracts in the vervet BMAA model.

### TABLE 2. Quantitative Analysis of pTDP-43\(^+\) Anterior Horn Motor Neurons

| Exposure Cohort | Cervical Segment | Lumbar Segment | All Spinal Cord Segments |
|-----------------|------------------|----------------|-------------------------|
| Rice flour      | 0.0 ± 0.8        | 0.0 ± 0.8      | 0.0 ± 0.7               |
| BMAA            | 3.0 ± 1.9        | 3.0 ± 3.1      | 4.5 ± 1.7*              |
| BMAA + L-serine | 3.0 ± 2.8        | 4.5 ± 3.6      | 3.8 ± 1.1NS             |

Median ± SEM of the number of TDP-43\(^+\) motor neurons per region of interest. n = 8 (rice flour vs BMAA); NS, no statistically significant differences were found using the Mann-Whitney U test.

\(*p = 0.02\).
Vervets dosed with rice flour (210 mg/kg/day) for 140 days had a normal distribution of quiescent microglia in anterior and posterior horns and both ascending and descending white matter tracts of the cervical spinal cord. Vervets dosed with the cyanobacterial toxin BMAA (210 mg/kg/day) displayed an increased density of activated Iba1+ microglia in ascending motor neuron pathways (blue arrow). Large focal and bilateral nodules of Iba1+ microglia were observed in the lateral corticospinal tracts (dotted squares). Microglial nodules (black arrow) varied in size and distribution adjacent to a vacuolated neuropil. A microglial nodule visualized with H&E staining. Corticospinal tracts, lateral (blue arrow) and anterior (white arrow), were positive for CD68, a marker for proinflammatory microglial activation. Large focal nodules of CD68+ microglia were observed (dotted square). Predominate focal (black arrow) and foamy phagocytic microglial nodules were present in BMAA toxin-dosed cohorts. A patient with sporadic ALS (sALS) displaying predominately diffused CD68+ microglial immunostaining evident of advanced disease stage. Scale bars: 1200 μm (left panel A–G), 1500 μm (left panel J), 500 μm (middle panel B–K), and 250 μm (right panel C–L).
MND patients for tolerability and efficacy of L-serine is underway (ClinicalTrials.gov Identifier: NCT03580616). Thus, pharmacological modulation of the serine pathway presents a promising therapeutic approach for treatment of ALS/MND. Our results provide preclinical evidence of the efficacy of L-serine and suggest that the BMAA exposure to vervets may be a useful model for testing compounds to slow or reverse the progression of motor neuron damage. Additional studies are needed in the vervet to determine the critical window and dose-related effects of L-serine when combined with BMAA.

FIGURE 6. L-Serine neuroprotection. (A–C) Topographical maps illustrating manual regional analysis of microglial activation in the cervical spinal cord for rice flour, BMAA, or BMAA + L-serine-dosed vervets. Each vervet is identified by a unique colored dot representing a large area of Iba1+ microglial activation or nodule. BMAA-dosed vervet cohorts had increased bilateral microglial activation in the lateral corticospinal tracts. Adjacent anatomical regions analyzed were unaffected. To determine the therapeutic effects of L-serine, automated image analyses were performed on lateral corticospinal tracts of each dosing cohort. (D) Chronic dietary dosing with BMAA (210 mg/kg/day) for 140 days increased the median density (pixel counts) by 1.7-fold (*p = 0.048; n = 8) and (E) the total area of the lateral corticospinal tracts covered by Iba1+ microglia by 1.6-fold (*p = 0.011; n = 8). (F) BMAA dosing did not have a significant effect on the size of Iba1+ microglia in the lateral corticospinal tracts (NS, p = 0.260; n = 8). (G) The distribution of CD68+ microglial nodule number and size (**p < 0.0001; n = 8) was increased in the cervical and lumbar (spinal cord) segments of toxin-exposed primates. (H) Coadministration of L-serine also reduced the effects of BMAA on CD68+ microglial nodule numbers, size, and expression intensity (**p = 0.01; n = 8).
exposure as well as the potential effects of augmenting L-serine to the diet after discontinuation of chronic BMAA exposures.

In conclusion, we demonstrate that chronic dietary exposure to the cyanobacterial toxin BMAA causes degeneration of the upper and lower motor neurons, activates microglia in the lateral corticospinal tracts, and induces proteinopathies with reactive astrogliosis in the anterior horns of the spinal cord that are characteristic of ALS/MND. The BMAA-dosed vervet can be used to model the neuropathology of Guam ALS/PDC and ALS/MND. The reduction of BMAA triggered pathology by L-serine supports the use of this amino acid as a therapeutic intervention to slow progression of the early stages of ALS/MND.

### TABLE 3. Quantitative Analysis of IbA1⁺ Microglia in the Lateral Corticospinal Tracts

| Group                  | Cervical Segment | Lumbar Segment |
|------------------------|------------------|----------------|
|                        | Total Area (Px)  | IbA1⁺ Density (Ct) | Size (Px) |
| Rice flour             | 16 067.5 ± 1442.3| 1084.3 ± 138.8   | 11.9 ± 1.1 |
| BMAA                   | 24 839.4 ± 4357.2*| 1831.8 ± 206.9*  | 15.4 ± 1.7SS |
| BMAA + L-serine        | 19 719.4 ± 1464.9*| 1691.1 ± 137.3SS | 14.1 ± 1.1 |
| Rice flour             | 15 285.4 ± 1336.9| 1398.3 ± 257.3   | 14.6 ± 7.5  |
| BMAA                   | 17 092.1 ± 2194.3SS| 1213.7 ± 151.5SS | 13.9 ± 1.9SS |
| BMAA + L-serine        | 12 379.3 ± 1388.1| 963.9 ± 152.2    | 11.8 ± 4.8  |

Median ± SEM of IbA1⁺ microglia automated measurements. n = 8 vervets per group; ANOVA test (cervical segments); NS, no statistical significance using Kruskal-Wallis test (lumbar segments); Ct, counts; Px, pixels.

*P ≤ 0.05.

### FIGURE 7. Myelinated axon fibers.
(A, D, G) Digitized pathology scans of a Luxol fast blue (LFB) counterstained with hematoxylin and eosin (H&E) spinal cord segment shown in low (3.3×), medium (11×), and high power (40×) from a vervet dosed with rice flour for 140 days. (B, E, H) Vervets cohorts dosed with the cyanotoxin, BMAA (210 mg/kg/day), for 140 days displayed pallor of staining of myelinated axon fibers in the lateral corticospinal tracts (dotted square). Loss of myelinated axon fiber staining was observed in 7 of 16 (44%) (NS, p = 0.0956; n = 8) of vervets exposed to the toxin. (C, F, I) Representative images of LFB/H&E-stained spinal cord segment from an individual with sALS for comparison. Scale bar: 1300 μm (A, B), 1900 μm (C), and 400 μm (D–F).
FIGURE 8. Corticospinal neuropathology. (A) Representative digital pathology scans of an NFT and a neuritic plaque observed in the cerebral cortex of vervets fed with BMAA (210 mg/kg/day) for 140 days. (B) The median cortical tau AT8\textsuperscript{+} NFT density was calculated by averaging automated density counts across the following seven brain regions: cingulate, entorhinal, frontal, insular, motor, occipital, and temporal cortices. BMAA dosing increased the median density of AT8\textsuperscript{+} NFTs 3.1-fold (***p < 0.0001; n = 8). The production of BMAA-induced tauopathy was partially blocked by coadministration of L-serine. (C) Cortical AT8\textsuperscript{+} NFT deposition in BMAA-dosed vervets was positively correlated with detectable levels of total BMAA in spinal cord tissues (r = 0.6804; ***p = 0.0004; n = 23); (D) the total area of Iba1\textsuperscript{+} microglia in the lateral corticospinal tract (r = 0.6399; ***p = 0.0003; n = 24); (E) the number of TDP-43\textsuperscript{+} cytoplasmic inclusions in anterior horn motor neurons (r = 0.4905; *p = 0.01; n = 24); and (F) the number of GFAP\textsuperscript{+} astroglia adjacent to motor neurons (r = 0.6488; ***p = 0.0004; n = 24). Coadministration of L-serine with BMAA reduced the observed pathology in the cerebral cortex and spinal cord of BMAA-dosed vervets. The solid black lines on scatter plots represent the best-fit line at 95% confidence interval. The red dotted lines indicate error. Scale bar: 25 \textmu m (A).
ACKNOWLEDGMENTS

We thank Dr Peter Wyatt of Queen Mary, University of London, for technical advice, Jane Cox for BMAA dose preparation, W. Broc Glover for sample preparation, Dr Elijah Stommel and Dr Thomas Coyne for valuable discussions, and the staff of the Miami Brain Endowment Bank at the Miller School of Medicine for management of the vervet biospecimen repository.

REFERENCES

1. Calvo A, Moglia C, Lunetta C, et al. Factors predicting survival in ALS: A multicenter Italian study. J Neurol 2017;264:54–63
2. Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: Implications for clinical management. Nat Rev Neurol 2017;13:96–104
3. Saberi S, Stauffer JE, Schulte DJ, et al. Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol Clin 2015;33:855–76
4. Lyon MS, Wossiski-Kuhn M, Gillespie R, et al. Inflammation, immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve 2019;59:10–22
5. McGoldrick P, Joyce PJ, Fisher EM, et al. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 2013;1832:1421–36
6. Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protocols Pharmacol 2015;69:671–21
7. Renton AE, Chio A, Traynor BJ, et al. Gene-environment-time interactions in neurodegenerative diseases: Hypotheses and research approaches. Ann Neurosci 2018;25:261–7
8. Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin 2015;33:807–30
9. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of glTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20–38
10. Ouyang K, Makifuchi T, Ohtoh T, et al. Amyotrophic lateral sclerosis of Guam: The nature of the neuropathological findings. Acta Neuropathol 1994;88:405–12
11. Whitng MG. Toxicity of caycads. Econ Bot 1963;17:270–302
12. Kurland LT. An appraisal of the neurotoxicity of caycads and the etiology of amyotrophic lateral sclerosis on Guam. Fed Proc 1972;31:1540–2
13. Bradley WG, Mash DC. Beyond Guam: The cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph Lateral Scler 2009;10:7–20
14. Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci U S A 2003;100:13380–3
15. Banack SA, Murch SJ, Cox PA. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J Ethnopharmacol 2006;106:107–104
16. Banack SA, Cox PA. Creating a Simian Model of Guam ALS/PDC which reflects Chamorro lifetime BMAA exposures. Neurotox Res 2018;33:24–32
17. Cox PA, Davis DA, Mash DC, et al. Dietary exposure to an environmental toxin triggers neurofibritary tangles and amyloid deposits in the brain. Proc Biol Sci 2016;283:20152539
18. Banack SA, Johnson HE, Cheng R, et al. Production of the neurotoxin BMAA by a marine cyanobacterium. Mar Drugs 2007;5:180–96
19. Cox PA, Banack SA, Murch SJ, et al. Diverse taxa of cyanobacteria produce beta-N-methylamino-L-alanine, a neurotoxic amino acid. Proc Natl Acad Sci U S A 2005;102:5074–8
20. Brand LE, Pablo J, Compton A, et al. Cyanobacterial blooms and the occurrence of the neurotoxin beta-N-methylamino-L-alanine (BMAA) in South Florida aquatic food webs. Harmful Algae 2010;9:620–35
21. Mondo K, Broc Glover W, Murch SJ, et al. Environmental neurotoxins beta-N-methylamino-L-alanine (BMAA) and mercury in shark cartilage dietary supplements. Food Chem Toxicol 2014;70:26–32
22. Banack SA, Metcalfe JS, Bradley WG, et al. Detection of cyanobacterial neurotoxin beta-N-methylamino-L-alanine within shellfish in the diet of an ALS patient in Florida. Toxicon 2014;90:167–73
23. Caller TA, Doolin JW, Haney JF, et al. A cluster of amyotrophic lateral sclerosis in New Hampshire: A possible role for toxic cyanobacteria blooms. Amyotroph Lateral Scler 2009;10(Supp 2):101–8
24. Xie X, Basile M, Mash DC. Cerebral uptake and protein incorporation of cyanobacterial toxin beta-N-methylamino-L-alanine. Neuroreport 2013;24:779–84
25. Tan VX, Mazocco C, Varney B, et al. Detection of the cyanotoxins L-BMAA uptake and accumulation in primary neurons and astrocytes. Neurotox Res 2018;33:55–61
26. Rao SD, Banack SA, Cox PA, et al. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol 2006;201:244–52
27. Albiano R, Loberd D. Transport of BMAA into neurons and astrocytes by system x_c. Neurotox Res 2018;33:1–5
28. Loberd D, Piana PM, Salous AK, et al. Beta-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis 2007;25:360–6
29. Ariti M, Kazim SF, Grundke-Iqbal I, et al. Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci U S A 2014;111:1144–9
30. Chiu AS, Gehenger MM, Braidy N, et al. Glutotoxicity of the cyanotoxin, beta-methyl-amino-L-alanine (BMAA). Sci Rep 2013;3:1482
31. Beri J, Nash T, Martin RM, et al. Exposure to BMAA mirrors molecular processes linked to neurodegenerative disease. Proteomics 2017;17:1700161.
32. Proctor EA, Mowrey DD, Dokholyan NV. beta-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology. PLoS Comput Biol 2019;15:e1007225
33. Glover WB, Baker TC, Murch SJ, et al. Determination of beta-N-methyl-amino-L-alanine, N-(2-aminoethyl)glycine, and 2,4-diaminobutyric acid in food products containing cyanobacteria by ultra-performance liquid chromatography and tandem mass spectrometry: Single-laboratory validation. J AOAC Int 2015;98:1559–65
34. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Reviewer Guidance: Validation of Chromatographic Methods. Washington, DC: Center for Drug Evaluation and Research 1994
35. Murch SJ, Cox PA, Banack SA, et al. Occurrence of beta-methylaminol-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand 2004;110:267–9
36. Pablo J, Banack SA, Cox PA, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease. Acta Neurol Scand 2009;120:216–25
37. Okamoto K, Mizuno Y, Fujita Y. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology 2008;28:109–15
38. Dodge JC, Treleaven CM, Fuller JA, et al. Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc Natl Acad Sci U S A 2013;110:10812–7
39. Robinson JL, Geser F, Stieber A, et al. TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol 2013;125:121–31
40. Strong MJ, Kesavapany S, Pant HC. The pathology of amyotrophic lateral sclerosis: A proteinopathy? J Neuropathol Exp Neurol 2005;64:649–64
41. Mori F, Tanji K, Zhang HX, et al. Maturation process of TDP-43 containing neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol 2008;116:193–203
42. Geser F, Winton MJ, Kwong LK, et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 2007;115:133–45
43. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010;9:995–1007
44. Maekawa S, Leigh PN, King A, et al. TDP-43 is consistently colocalized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology 2009;29:672–83
45. Yan HZ, Yu S, Hsu CT, et al. Intracellular infusion of a BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord. Exp Neurol 2014;261:1–9
46. D’Mello F, Braidy N, Marcal H, et al. Cytotoxic effects of environmental toxins on human glial cells. Neurotox Res 2017;31:245–58
47. Geloso MC, Corvino V, Marchese E, et al. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. Front Aging Neurosci 2017;9:242
49. Singh S, Metz I, Amor S, et al. Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol 2013;125:595–608
50. Cox PA, Davis DA, Mash DC, et al. Do vervets and macaques respond differently to BMAA? Neurotoxicology 2016;57:310–1
51. Takeda T. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neuropathology 2018;38:72–81
52. Fainman J, Eid MD, Ervin FR, et al. A primate model for Alzheimer’s disease: Investigation of the apolipoprotein E profile of the vervet monkey of St. Kitts. Am J Med Genet B Genet 2007;144B: 818–9
53. Oyanagi K, Wada M. Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: An update. J Neurol 1999;246(Suppl 2):II19–27
54. Dunlop RA, Cox PA, Banack SA, et al. The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation. PLoS One 2013;8:e75376
55. Dunlop RA, Powell JT, Metcalf JS, et al. L-Serine-mediated neuroprotection includes the upregulation of the ER stress chaperone protein disulfide isomerase (PDI). Neurotox Res 2018;33:113–22
56. Wang G, Ding L, Gao C, et al. Neuroprotective effect of L-serine against white matter demyelination by harnessing and modulating inflammation in mice. Neuropharmacology 2019;146:39–49
57. Beltran-Castillo S, Eugenin J, von Bernhardi R. Impact of aging in microglia-mediated D-serine balance in the CNS. Mediators Inflamm 2018;2018:7219732
58. Daniels BA, Wood L, Tremblay F, et al. Functional evidence for D-serine inhibition of non-N-methyl-D-aspartate ionotropic glutamate receptors in retinal neurons. Eur J Neurosci 2012;35:56–65
59. Wolosker H, Balu DT, Coyle JT. The rise and fall of the D-serine-mediated gliotransmission hypothesis. Trends Neurosci 2016;39:712–21
60. Metcalf JS, Dunlop RA, Powell JT, et al. L-Serine: A naturally-occurring amino acid with therapeutic potential. Neurotox Res 2018;33:213–21
61. Levine TD, Miller RG, Bradley WG, et al. Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:107–11
62. Zhai PP, Xu LH, Yang JJ, et al. Reduction of inflammatory responses by L-serine treatment leads to neuroprotection in mice after traumatic brain injury. Neuropharmacology 2015;95:1–11
63. Ren TJ, Qiang R, Jiang ZL, et al. Improvement in regional CBF by L-serine contributes to its neuroprotective effect in rats after focal cerebral ischemia. PLoS One 2013;8:e67044